Highly Active Antiretroviral Therapy for Patients With Primary Biliary Cirrhosis

Primary Biliary Cirrhosis Clinical Trial

— HAART  

Official title:

Randomized Controlled Pilot Study of Highly Active Anti-Retroviral Therapy for Patients With Primary Biliary Cirrhosis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01614405
• Other study ID #: HAART Study
• Status: Completed
• Phase: N/A
• First received: April 25, 2011
• Last updated: November 30, 2015
• Start date: June 2012
• Est. completion date: August 2015

Study information

• Verified date: December 2014
• Source: University of Alberta
• Contact: n/a
• Is FDA regulated: No
• Health authority: Canada: Health CanadaUnited States: Institutional Review BoardFrance: Ministry of Health
• Study type: Interventional

Clinical Trial Summary

Patients with primary biliary cirrhosis (PBC) develop progressive liver disease and often require liver transplantation. The cause of disease is unknown. It is thought to occur as a result of an infection in subjects that are more susceptible to disease than others. The investigators found evidence of retrovirus infection in patients with primary biliary cirrhosis. The investigators found that most patients with PBC have evidence of viral infection. Since then the investigators have conducted clinical studies using anti-viral therapy. The investigators found that PBC patients treated with combination anti-retrovirus therapy experienced significant reversal of the disease process. However, the changes were not substantial and the investigators are now looking for better antiviral regimens. Now the investigators have found a mouse model with a similar virus infection that develops a similar biliary disease. Importantly, the investigators found that antiviral therapy blocks the development of the disease in this mouse. The investigators have used this model to find safer and more effective antiviral treatments for patients with PBC. The investigators have now found out that a combination of highly active antiretroviral therapy with Truvada and Kaletra stops disease in the mouse and plan to use this combination to see if it works in patients with PBC.

Description:

6 months therapy with blinded Kaletra and Truvada vs. 6 months therapy with blinded placebo followed by 6 months open label therapy with Kaletra and Truvada

18 month extension study with open label Kaletra and Truvada in patients completing 6 months of therapy with Kaletra and Truvada with biochemical endpoint

Recruitment information / eligibility

• Status: Completed
• Enrollment: 13
• Est. completion date: August 2015
• Est. primary completion date: July 2015
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Patients 18 years old of either sex will be recruited for this study.

2. Elevated ALP after 6 months UDCA therapy = 2 x upper limit of normal or abnormal bilirubin.

3. Positive serum AMA or Liver biopsy histology compatible with PBC.

4. Maintained on UDCA at a dose of 13-15 mg/kg for 6 or more months.

5. Patients must read and sign informed consent form

Exclusion Criteria:

1. Subjects with baseline AST or ALT > 5 x ULN.

2. Patients who have altered dose of any medications used to treat PBC (such as UDCA) or the use of colchicine, corticosteroids, azathioprine, chlorambucil, methotrexate, or D-penicillamine within the last 6 months.

3. Advanced liver disease or esophageal varices, INR > 1.2 (upper limit of normal), Albumin < 35 g/L (lower limit of normal), platelets < 120,000/mm3, Childs Pugh class B or C cirrhosis, presence of varices or previous variceal hemorrhage, spontaneous encephalopathy, ascites or need for liver transplantation.

4. Patients with a secondary diagnosis such as HIV, viral hepatitis, drug induced liver injury, extrahepatic biliary obstruction, primary sclerosing cholangitis, metabolic liver diseases or alcoholic liver disease Regular use of more than 30 g of alcohol per day in the last year. Clinically apparent pancreatitis or with a predicted survival of less than 3 years from malignant or other potentially life threatening disease.

5. An ultrasound showing a hepatic mass consistent with hepatocellular carcinoma within the last year in patients with cirrhosis.

6. Previous allergic reaction to study medications.

7. Creatinine clearance less than < 70 mL/min using the Cockcroft Gault equation:

Creatinine clearance (mL/min) = (140 - age) x body wt (Kg) x 0.85 (if female)/serum creatinine in mol/l

8. Pregnancy or breast-feeding a child. Young sexually active patients not using contraception

9. Young sexually active patients not using contraception.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Liver Cirrhosis
• Liver Cirrhosis, Biliary
• Primary Biliary Cirrhosis

Intervention

Drug:
• Truvada and Kaletra
one tablet of Truvada a day at standard dose of Tenofovir 300mg and Emtricitabine 200mg and four tablets of Kaletra once a day for a total dose of lopinavir 800mg and ritonavir 200mg for 6 months or less if adverse events occur

Locations

Country	Name	City	State
Canada	University of Alberta	Edmonton	Alberta

Sponsors (4)

Lead Sponsor	Collaborator
University of Alberta	Abbott, Canadian Institutes of Health Research (CIHR), Gilead Sciences

Country where clinical trial is conducted

Canada, 

References & Publications (1)

Schembri G, Schober P. Killing two birds with one stone. Lancet. 2011 Jan 1;377(9759):96. doi: 10.1016/S0140-6736(10)61343-8. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Reduction of ALP to 1.67x ULN		The outcomes will be measured are from 12 to 24 weeks at the end of the study	Yes
Primary	normalization of bilirubin.		The outcomes will be measured are from 12 to 24 weeks at the end of the study	Yes
Secondary	Reduction of human betaretrovirus.		The outcomes will be measured are from 12 to 24 weeks in RCT; and 6 monthly to 2 years for the extension study	No
Secondary	Symptoms with changes in PBC-40		The outcomes will be measured are from 12 to 24 weeks in RCT; and 6 monthly to 2 years for the extension study	No
Secondary	Changes in AMA and immunoglobulin levels		The outcomes will be measured are from 12 to 24 weeks in RCT; and 6 monthly to 2 years for the extension study	No
Secondary	Biochemistry: GGT, AST and ALT		The outcomes will be measured are from 12 to 24 weeks in RCT; and 6 monthly to 2 years for the extension study	Yes
Secondary	Histology in extension study		The outcomes will be measured are from 12 to 24 weeks in RCT; and 6 monthly to 2 years for the extension study	Yes